TIAM1–RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy
- Renu A. KowluruAffiliated withDepartment of Ophthalmology, Wayne State University
- , Anjaneyulu KowluruAffiliated withDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityJohn D. Dingell VA Medical Center Email author
- , Rajakrishnan VeluthakalAffiliated withDepartment of Ophthalmology, Wayne State University
- , Ghulam MohammadAffiliated withDepartment of Ophthalmology, Wayne State UniversityDepartment of Ophthalmology, King Saud University
- , Ismail SyedAffiliated withDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityDepartment of Endocrinology, Diabetes and Metabolism, Beth Israel Hospital, Harvard Medical School
- , Julia M. SantosAffiliated withDepartment of Ophthalmology, Wayne State University
- , Manish MishraAffiliated withDepartment of Ophthalmology, Wayne State University
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In diabetes, increased retinal oxidative stress is seen before the mitochondria are damaged. Phagocyte-like NADPH oxidase-2 (NOX2) is the predominant cytosolic source of reactive oxygen species (ROS). Activation of Ras-related C3 botulinum toxin substrate 1 (RAC1), a NOX2 holoenzyme member, is necessary for NOX2 activation and ROS generation. In this study we assessed the role of T cell lymphoma invasion and metastasis (TIAM1), a guanine nucleotide exchange factor for RAC1, in RAC1 and NOX2 activation and the onset of mitochondrial dysfunction in in vitro and in vivo models of glucotoxicity and diabetes.
RAC1 and NOX2 activation, ROS generation, mitochondrial damage and cell apoptosis were quantified in bovine retinal endothelial cells exposed to high glucose concentrations, in the retina from normal and streptozotocin-induced diabetic rats and mice, and the retina from human donors with diabetic retinopathy.
High glucose activated RAC1 and NOX2 (expression and activity) and increased ROS in endothelial cells before increasing mitochondrial ROS and mitochondrial DNA (mtDNA) damage. N6-[2-[[4-(diethylamino)-1-methylbutyl]amino]-6-methyl-4-pyrimidinyl]-2-methyl-4,6-quinolinediamine, trihydrochloride (NSC23766), a known inhibitor of TIAM1–RAC1, markedly attenuated RAC1 activation, total and mitochondrial ROS, mtDNA damage and cell apoptosis. An increase in NOX2 expression and membrane association of RAC1 and p47phox were also seen in diabetic rat retina. Administration of NSC23766 to diabetic mice attenuated retinal RAC1 activation and ROS generation. RAC1 activation and p47phox expression were also increased in the retinal microvasculature from human donors with diabetic retinopathy.
The TIAM1–RAC1–NOX2 signalling axis is activated in the initial stages of diabetes to increase intracellular ROS leading to mitochondrial damage and accelerated capillary cell apoptosis. Strategies targeting TIAM1–RAC1 signalling could have the potential to halt the progression of diabetic retinopathy in the early stages of the disease.
KeywordsDiabetic retinopathy Mitochondrial dysfunction NOX2 RAC1 TIAM1
- TIAM1–RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy
Volume 57, Issue 5 , pp 1047-1056
- Cover Date
- Print ISSN
- Online ISSN
- Springer Berlin Heidelberg
- Additional Links
- Diabetic retinopathy
- Mitochondrial dysfunction
- Industry Sectors
- Author Affiliations
- 1. Department of Ophthalmology, Wayne State University, Detroit, MI, USA
- 2. Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Avenue, Detroit, MI, 48201, USA
- 3. John D. Dingell VA Medical Center, Detroit, MI, USA
- 4. Department of Ophthalmology, King Saud University, Riyadh, Saudi Arabia
- 5. Department of Endocrinology, Diabetes and Metabolism, Beth Israel Hospital, Harvard Medical School, Boston, MA, USA